LENZ Therapeutics Inc (LENZ NASDAQ) stock market data APIs
$22.8374
-0.62(-2.7%)
as of November 7, 2025
Try our APIs with
free plan!
LENZ Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
LENZ Therapeutics, Inc. operates as a biopharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.
Prev. Close
22.8374
Open
22.2149
High
23.9967
Low
22.2135
52 wk Range
16.535-50.4
Market Cap
719 M
Shares Outstanding
31 290 K
Revenue
17 500 K
EPS
-0.59
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with LENZ Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get LENZ Therapeutics Inc data using free add-ons & libraries
Get LENZ Therapeutics Inc Fundamental Data
LENZ Therapeutics Inc Fundamental data includes:
- Net Revenue: 17 500 K
- EBITDA: -67 695 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-09-30
- EPS/Forecast: -0.6891
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
LENZ Therapeutics Inc News
New
LENZ Therapeutics, Inc. (LENZ) Reports Q3 Loss, Beats Revenue Estimates
LENZ Therapeutics, Inc. (LENZ) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.67. This compares to a loss of $0.38 per share a year ago. These fi...
Staar Surgical, Insight Enterprises, and More Stocks See Action From Activist Investors
13D FILINGS These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity’s attaining more than 5% in any class of a company’s securities. Continue Reading View Comments
Jim Cramer Says “LENZ Therapeutics Has a Promising Story”
LENZ Therapeutics, Inc. (NASDAQ:LENZ) is one of the stocks Jim Cramer recently gave takes on. Commenting on the company’s eyedrops, VIZZ, Cramer said: “Overall, I’m inclined to believe that the...
LENZ Therapeutics stock price target raised to $56 from $48 at H.C. Wainwright
Investing.com - H.C. Wainwright raised its price target on LENZ Therapeutics Inc (NASDAQ:LENZ) to $56.00 from $48.00 on Friday, while maintaining a Buy rating on the stock. The company, currently trad...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
